Consultation: Release of Draft (Step 2) ICH S9 Q&As: Questions and Answers: Nonclinical Evaluation for Anticancer Pharmaceuticals
The above referenced draft guidance was released by the ICH Steering Committee for consultation and is being posted on the ICH website for information and comment in accordance with Step 2 of the ICH process.
How to Get Involved
This consultation is open for comment starting July 29, 2016 until October 27, 2016. Please select and read through the link below titled "consultation document". Once read, please submit your comments via email, fax or by mail to:
Jian Wang
Centre for Evaluation of Radiopharmaceuticals and Biotherapeutics
Biologics and Genetic Therapies Directorate
Health Products and Food Branch
Health Canada
100 Eglantine Driveway, Tunney's Pasture
Ottawa, Ontario
K1A 0K9
E-mail: Jian.wang@hc-sc.gc.ca
Telephone: 613-293-1849
Fax: 613-946-0639
Interested parties are encouraged to provide comments and suggestions by October 27, 2016.
Reporting to Canadians
Health Canada will make the results of this consultation available on this Web site. If you have any questions, contact Jian.wang@hc-sc.gc.ca.
Interested in our other consultations? Sign up and stay informed about topics that matter to you.